Acadia Pharma (ACAD) Misses Q1 EPS by 10c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $20.76 +2.17%
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
PFBX, GOVB, VABK, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
PFBX, GOVB, VABK, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.70), $0.10 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $115.5 million versus the consensus estimate of $121.92 million.
GUIDANCE:
Acadia Pharma sees FY2022 revenue of $510-560 million, versus the consensus of $540.7 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Alignment Healthcare, Inc. (ALHC) Reports In-Line Q3 EPS; offers guidance
- Portland General Electric (POR) Misses Q3 EPS by 13c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
